Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Other Operating Expenses (2016 - 2024)

Perspective Therapeutics' Other Operating Expenses history spans 15 years, with the latest figure at -$27000.0 for Q4 2024.

  • On a quarterly basis, Other Operating Expenses fell 222.73% to -$27000.0 in Q4 2024 year-over-year; TTM through Sep 2025 was -$27000.0, a 222.73% decrease, with the full-year FY2024 number at -$27000.0, changed N/A from a year prior.
  • Other Operating Expenses hit -$27000.0 in Q4 2024 for Perspective Therapeutics, down from $22000.0 in the prior quarter.
  • Over the last five years, Other Operating Expenses for CATX hit a ceiling of $1.6 million in Q1 2022 and a floor of -$7.9 million in Q3 2022.
  • Historically, Other Operating Expenses has averaged -$699153.8 across 5 years, with a median of -$2000.0 in 2021.
  • Biggest five-year swings in Other Operating Expenses: surged 80400.0% in 2020 and later crashed 1134.3% in 2022.
  • Tracing CATX's Other Operating Expenses over 5 years: stood at -$7000.0 in 2020, then skyrocketed by 10971.43% to $761000.0 in 2021, then plummeted by 140.08% to -$305000.0 in 2022, then skyrocketed by 107.21% to $22000.0 in 2023, then plummeted by 222.73% to -$27000.0 in 2024.
  • Business Quant data shows Other Operating Expenses for CATX at -$27000.0 in Q4 2024, $22000.0 in Q4 2023, and -$22000.0 in Q1 2023.